You are subscribed to the FormularyWatch.

Formulary

eNewsletter Subscribe

March 30 2015

Web Version  | Share with a colleague

Facebook Like Twitter Tweet

Today's Headlines

New HHS plan on opioids ups naloxone use

Health and Human Services (HHS) recently launched a widespread initiative—including increasing the use of naloxone to reverse opioid overdoses—aimed at reducing prescription opioid-and heroin-related overdose, death and dependence. » Read more

Study: Medication effectiveness diminishes when patients crush tablets

People who take more than 4 doses of medicine a day appear more likely to crush tablets or open capsules potentially reducing their effectiveness, according to a study published in the Journal of Pharmacy Practice and Research. » Read more

Continuing Education

2015 Updates on the national guidelines for diabetes management and related disorders

Last month and this month pharmacists will be able to learn about the latest developments in diabetes treatment and management. Pharmacists can earn up to 4 hours of CPE credit with two monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics. The goal of this month's activity is to discuss the recent updates of national U.S. guidelines for diabetes management, including hypertension and cholesterol management in patients with diabetes, in order to empower pharmacists in clinical decision-making.

Read/print the article: Click here

Take the test: Click here to log in with the Session Code 15DT16-TAJ88.


Announcement: Our CE activities have moved to a new learning management system to better serve you. The login to the Online CE Center is https://web2.uconn.edu/pharmacyce/login.php. All current user registration information has been uploaded for your convenience. Current users do not need to register. To review your registration page to ensure the data is up to date or to register, go to https://web2.uconn.edu/pharmacyce/program_register.php. For a full list of courses, go to http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce/

EDITOR'S PICK

Current nonsurgical treatment options for stage III, stage IV, recurrent melanoma

Until recently, pharmacologic options for advanced melanoma were very limited. » The newest advances

POLL:

A new class of biologics in the PCSK9 Inhibitors likely will be approved for treating high cholesterol. How are you preparing?

 

RELATED ARTICLES

Naloxone price increases may threaten public safety

Pharmacist interventions improve diabetes outcomes

RESOURCES

Latest Clinical News

Powered by Modern Medicine Advanstar Medical Communications Group